Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00044512 |
Evaluate anti-cancer activity (e.g. proportion of patients with confirmed complete response or partial response) in patients with advanced, inoperable biopsy-proven hepatocellular carcinoma.
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Hepatocellular |
Drug: Nexavar (Sorafenib, BAY43-9006) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Multicenter Uncontrolled Trial of BAY 43-9006 in Patients With Advanced Hepatocellular Carcinoma |
Enrollment: | 147 |
Study Start Date: | August 2002 |
Study Completion Date: | February 2008 |
Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental |
Drug: Nexavar (Sorafenib, BAY43-9006)
Multi Kinase Inhibitor (BAY 43-9006 400 mg bid daily)
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Los Angeles, California, United States, 90057 | |
United States, New York | |
New York, New York, United States, 10021-6007 | |
Belgium | |
BRUXELLES - BRUSSEL, Belgium, 1000 | |
GENT, Belgium, 9000 | |
BRUXELLES - BRUSSEL, Belgium, 1070 | |
BRUXELLES - BRUSSEL, Belgium, 1090 | |
LEUVEN, Belgium, 3000 | |
France | |
SAINT HERBLAIN, France, 44805 | |
MARSEILLE, France, 13005 | |
RENNES CEDEX, France, 35062 | |
PARIS, France, 75020 | |
LILLE CEDEX, France, 59020 | |
Israel | |
Tel Aviv, Israel, 64239 | |
Rehovot, Israel, 76100 | |
Jerusalem, Israel, 91120 | |
Tel Hashomer, Israel, 52621 | |
Petach Tikva, Israel, 49100 | |
Haifa, Israel, 31096 | |
Italy | |
Forlì, Italy, 47100 | |
Pisa, Italy, 56126 | |
Verona, Italy, 37126 | |
Milano, Italy, 20122 | |
Italy, Milano | |
Rozzano, Milano, Italy, 20089 |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer HealtCare Pharmaceuticals ( Therapeutic Area Head ) |
Study ID Numbers: | 10874 |
Study First Received: | August 30, 2002 |
Last Updated: | October 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00044512 |
Health Authority: | United States: Food and Drug Administration |
Cancer Liver Cancer Hepatocellular carcinoma (HCC) |
Liver Neoplasms Liver Diseases Digestive System Diseases Digestive System Neoplasms Carcinoma, Hepatocellular Liver neoplasms |
Gastrointestinal Neoplasms Adenocarcinoma Sorafenib Hepatocellular carcinoma Neoplasms, Glandular and Epithelial Carcinoma |
Neoplasms Neoplasms by Site Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |